UNSPSC 51282127: Tazobactam

This classification denotes a penicillin antibiotic, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier SE10G96M8W. The European Medicines Agency schedules Tazobactam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10849MIG. Tazobactam generally arises in the molecular formula C10H12N4O5S.

The term TAZOBACTAM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 3, no. 3, 1989, list 29.) TAZOBACTAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3.

UNSPSC 51282127 Tazobactam, a Commodity code, nominally names a specific beta-lactamase inhibitor pharmaceutical, but the recent state and local opportunities tagged under it show little direct procurement activity for tazobactam itself. Instead, the code appears in state and local procurement systems alongside other pharmaceutical and medical-supply purchases — including antibiotic tablets, naloxone, and drug deactivation systems — suggesting either broad tagging of pharmaceutical inventory categories or misclassification in source data. State and local issuing bodies using this code span health departments and county health offices. The Illinois Department of Public Health procures pharmaceutical warehouse supplies through cooperative purchasing vehicles such as MMCAP Infuse, and Seminole County, Florida purchases naloxone and drug deactivation systems to support community health initiatives. Neither opportunity directly specifies tazobactam procurement.

Recent activity appears concentrated in the Southeast and Midwest. Illinois issued a piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC for $2,999,999.11 over 12 months with two renewal options, awarded via IFB on August 28, 2026, though the specific products were doxycycline and ciprofloxacin, not tazobactam. Seminole County, Florida issued an IFB for naloxone and drug deactivation systems with a due date of July 26, 2026, seeking 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. Business development professionals evaluating this code should verify whether tazobactam-specific procurement activity exists under different codes or in state formulary or GPO cooperative purchasing arrangements, as the recent record does not support direct tazobactam solicitation at the state or local level.